Table 2.
Induction of remission therapy and glucocorticoid use
| Induction regimen | |
| Combination therapy (RTX + low-dose CYC)a | 43 (47%) |
| RTX | 44 (48%) |
| CYC (standard dosing) | 2 (2%) |
| Other | 2 (2%) |
| Plasma exchange | 13 (14%) |
| Methylprednisolone | |
| Received i.v. pulse | 59 (64%) |
| Cumulative dose, mg | 1340 (1319) |
| Prednisone, mg | |
| Dose at wk 26 | 1.8 (3.7) |
| Dose at wk 52 | 0.6 (2.5) |
| Cumulative dose at wk 12 | 1797 (1104) |
| Cumulative dose at wk 52 | 2212 (1550) |
| Off prednisone (as of last follow-up) | 64 (72%) |
| Time to start avacopan (from start of induction), wk | 3.6 (2.1–7.7) |
| Time to stop prednisone (from start of avacopan), wk | 5.6 (3.3–9.5) |
CYC, cyclophosphamide; RTX, rituximab.
Values are presented as either number (%), median (IQR), or mean ± (SD).
a
Typically, 8 weeks of daily oral CYC treatment, beginning with the first dose of RTX. Dosing was typically 2.5 mg/kg/d for the first week and 1.5 mg/kg/d for 7 weeks, with adjustments made for kidney function.